PipelineReview.com (press release) One of the company's most important product candidates is the DNA immunomodulator MGN1703, which is being clinically developed for colorectal cancer and non-small cell lung cancer. The cell-based cancer therapy MGN1601 for the treatment of ...
GlobeNewswire (press release) ... Dr. Schaible's group designed and conducted the SONIC trial in Crohn's disease, a major clinical trial published in the New England Journal of Medicine, demonstrating the superiority of REMICADE® versus a conventional immunomodulator (azathioprine) ...
GlobeNewswire (press release) ... Dr. Schaible's group designed and conducted the SONIC trial in Crohn's disease, a major clinical trial published in the New England Journal of Medicine, demonstrating the superiority of REMICADE® versus a conventional immunomodulator (azathioprine) ...
Vancouver Sun (blog) Sutcliffe and Gunn are taking a fresh approach to Coley's Toxins. They've teamed up in a biopharma company Gunn formed called Qu Biologics. It has just launched its first clinical trial on an immune-stimulating drug called a Site Specific ...
